A Prospective Observational Study on Treatment of Atrial Fibrillation Withor Without Beta-Blockers.

Background: Atrial fibrillation is a common heart rhythm disorder characterized by irregular and rapid electrical impulses in the atria. It can lead to symptoms like palpitations, dizziness, and shortness of breath. Managing Atrial fibrillation is crucial to prevent complications such as stroke and heart failure. Beta blockers play a vital role in atrial fibrillation management by slowing down the heart rate and reducing the frequency of irregular heartbeats. Non-beta blockers, such as calcium channel blockers and other antiarrhythmic medications, are used in atrial fibrillation to control heart rate and restore normal rhythm. The disagreement between beta blockers and non-beta blockers Research Gap: for the treatment of atrial fibrillation stems from differences in their mechanisms of action and potential side effects. The research gap between beta blockers and non-beta blockers in the treatment of atrial fibrillation lies in the need for more comparative studies to assess their efficacy and safety profiles. A prospective cohort analysis was Methodology: conducted using medical records of patients diagnosed with Atrial fibrillation at a tertiary care center. The cohort comprised 61 patients on beta blockers and 39 patients on non-beta blocker treatments. The Results And Conclusion: cohort analysis revealed that the beta blocker group demonstrated a significantly lower rate of hospital readmissions compared to the non-beta blocker group (p < 0.05). Moreover, patients on beta blockers exhibited a greater improvement in cardiac function parameters, compared to non-beta blocker treatments (p < 0.05). Future Prospects: Therefore, more investigations are essential to guide personalized and optimized treatment strategies for atrial fibrillation patients.